36% EBITDA Growth, But Guidance Stayed Put

On the surface this is a blowout: 25% revenue growth, 41% profit growth, EBITDA surging 36% year-on-year to ₹209 Cr — a 15-quarter high. But read the call and the tension becomes clear. Of that 36% EBITDA growth, roughly half came from acetyl pricing (a commodity surge) and CDMO volume ramps that management flagged as timing-dependent and inherently lumpy. The large CDMO agro contract, worth $300M over five years, didn't serve full Q1 volumes due to customer-requested delays on raw material pricing. And despite hitting every line item, management maintained FY27 guidance at ₹750–800 Cr EBITDA rather than raising it. That refusal is the story.

Three clear narratives: Specialty Chemicals is the CDMO/fine chemicals franchise, margins at 26% reflecting the higher-value mix, but the large agro contract underdelivered volumes in Q1 (customer pause on raw materials, now set to ramp in Q2+). Nutrition hit its 3-year EBITDA high on niacinamide plant utilization climbing to 50% and moving toward 70%, combined with B3 pricing strength — though management noted historical precedent suggests B3 may decline by end-Q2. Chemical Intermediates is the quarter's surprise: revenue up 38%, but EBITDA up 240%, driven entirely by acetyl pricing surge from Gulf supply disruptions. This is the outlier. Management was explicit on the call: acetyl pricing is commodity-exposed, and sustainability is uncertain heading into Q3–Q4.

The first three claims hold up exactly. Revenue +25.3%, PAT +40.9%, margins holding. The CDMO claim is overstated: the large agro contract did make positive EBITDA in Q1, but volumes were deferred due to customer delays, and the full upside is pushed to Q2+. Management said: 'We did not serve the full volumes last quarter as the innovator had confirmed because... the raw material prices had escalated due to war and the innovator asked us to take a temporary pause till pricing came down.' That's a real risk to Q2+ delivery. The sequential growth claim is supported by the mechanics — all three segments showing positive momentum — but hinges on CDMO ramp timing and commodity prices holding.

The stock closed the day of the result at ₹743.75 and moved just +0.17% the next day — a muted reaction for a quarter that beat guidance and delivered record volumes. That tepid move is the market's own verdict: priced in. The stock is now ₹745, trading 6.21% off its all-time high of ₹794.3, but +38.66% from its 52-week low. It sits above all three key moving averages (SMA20, SMA50, SMA200), a bullish setup, but RSI at 65 signals neutral overbought conditions — room to run but no euphoria. Institutional ownership: FII steady at 6.49%, DII up 76 basis points to 24.76%, promoter flat at 45.22%. Volume trend increasing. The picture: a solid franchise that has already moved, now asking for growth to continue accelerating. Next quarter will be the test — CDMO volumes, acetyl prices, and the path to FY27 guidance.